Merck & Co. Inc. is buying Cidara Therapeutics Inc. for $9.2 billion to acquire a late-stage flu candidate and also to outrace blockbuster Keytruda’s looming patent expiration. CD-388, Cidara’s lead ...
Ongoing disruptions in federal funding are causing many young brain scientists to reconsider their career choice, according ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback